PLSE Reports Q4 2025 Earnings with Revenue Growth and Mixed Financial Performance
PLSE reported Q4 2025 earnings with revenue increasing to $264,000 from Vybrance systems and electrodes, up from $86,000 in Q3. The company saw a decrease in GAAP costs and expenses but an increase in non-GAAP costs, while cash reserves declined sequentially. The results reflect mixed financial performance with both improvements and challenges.
Tickers: $PLSE
Topics: cash flow clinical trials earnings expenses intellectual property net loss revenue